LiveWire Ergogenics (LVVV) AI Stock Analysis

• Market Cap: $951.99K
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): 177.10
• Revenue Growth: -81.39%
• EPS Growth: -100.00%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 1,903,979,100
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: -0.14
• Price to Book (P/B): 0.35
• Price to Sales (P/S): 3.71
• P/FCF Ratio: 9.05
• Enterprise Value/Market Cap: 4.92
• Enterprise Value/Revenue: 598.25
• Enterprise Value/Gross Profit: -975.91
• Enterprise Value/Ebitda: -57.05
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.01 ▲(1150.00% Upside)
• Action: Reiterated Date: 12/11/25
• Date: Action: Reiterated 12/11/25

The overall stock score for LiveWire Ergogenics is primarily driven by significant challenges in financial performance, including declining revenue and cash flow. The absence of technical indicators further impacts the score negatively. The lack of valuation data and earnings call information limits the ability to provide a more comprehensive assessment.

Positive Factors

Cost Management

Efficient cost management allows LiveWire Ergogenics to preserve margins despite declining revenue, indicating operational resilience.

Leverage Management

Improved leverage management suggests a more sustainable financial structure, enhancing long-term stability and reducing risk.

Cash Flow Stability

Maintaining a positive free cash flow to net income ratio indicates some level of cash flow stability, crucial for ongoing operations and investments.

Negative Factors

Revenue Decline

Significant revenue decline poses a risk to financial health, potentially impacting the company's ability to invest in growth and innovation.

Cash Generation Challenges

Decreased cash flow generation limits financial flexibility, affecting the company's capacity to fund operations and strategic initiatives.

Profitability Challenges

Declining net profit margins reflect challenges in maintaining profitability, which could hinder long-term growth and shareholder returns.

LiveWire Ergogenics Business Overview & Revenue Model

Company Description

LiveWire Ergogenics Inc. focuses on acquiring, managing, and licensing special purpose real estate properties to produce handcrafted and organically grown cannabis products for medical and recreational adult-use in California. The company is based in Anaheim, California.

How the Company Makes Money

LiveWire Ergogenics generates revenue primarily through the sale of its CBD and hemp-derived products. The company has established a multi-channel distribution strategy that includes direct-to-consumer sales, partnerships with retail outlets, and e-commerce platforms. Key revenue streams include product sales, subscription services, and potential licensing agreements for its proprietary formulations. Additionally, the company's strategic partnerships with other entities in the cannabis industry enhance its market reach and provide opportunities for collaborative product development, further contributing to its earnings.

LiveWire Ergogenics Financial Statement Overview

Summary

LiveWire Ergogenics faces significant challenges with declining revenue and cash flow, impacting overall financial performance. While the company demonstrates strong cost management and improved leverage, the declining profitability and cash generation pose risks to financial stability. Continued focus on revenue growth and cash flow improvement is essential for future success.

Income Statement

LiveWire Ergogenics has experienced a significant decline in revenue, with a 72.31% drop in the most recent year. Despite this, the company maintains strong gross and EBIT margins, indicating efficient cost management. However, the net profit margin has decreased from previous years, reflecting challenges in maintaining profitability amidst declining sales.

Balance Sheet

The company's debt-to-equity ratio has improved slightly, indicating better leverage management compared to previous years. However, the equity ratio remains low, suggesting potential risks related to financial stability. The return on equity has decreased, highlighting challenges in generating returns for shareholders.

Cash Flow

Free cash flow has significantly decreased, reflecting challenges in cash generation. The operating cash flow to net income ratio is low, indicating potential difficulties in converting income into cash. Despite these challenges, the company maintains a positive free cash flow to net income ratio, suggesting some level of cash flow stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.83K	304.12K	1.63M	1.94M	851.20K	580.32K
Gross Profit	-4.80K	285.16K	1.59M	1.80M	701.55K	376.51K
EBITDA	-82.17K	322.18K	1.22M	1.07M	-2.68M	-302.00K
Net Income	-1.17M	78.72K	921.58K	684.12K	-3.43M	-1.60M
Balance Sheet
Total Assets	2.63M	7.96M	7.74M	6.27M	4.52M	2.91M
Cash, Cash Equivalents and Short-Term Investments	1.67K	11.27K	27.87K	76.38K	199.95K	109.88K
Total Debt	3.53M	3.35M	3.34M	3.20M	2.85M	3.23M
Total Liabilities	4.16M	4.70M	4.62M	4.24M	3.61M	3.99M
Stockholders Equity	-1.54M	3.24M	3.11M	2.03M	912.13K	-1.08M
Cash Flow
Free Cash Flow	11.44K	124.74K	682.37K	396.37K	-467.21K	315.33K
Operating Cash Flow	11.43K	124.74K	682.37K	396.37K	-399.89K	356.16K
Investing Cash Flow	0.00	-187.34K	-857.40K	-1.20M	-930.51K	-874.12K
Financing Cash Flow	0.00	46.00K	126.51K	684.50K	1.42M	627.84K

LiveWire Ergogenics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRMA	47 Neutral	$3.37M	-0.76	-203.36%	―	―	90.53%
PRFX	44 Neutral	$2.18M	-0.13	―	―	―	―
LVVV	41 Neutral	$951.99K	-0.66	―	―	-81.39%	-100.00%
MSPR	40 Underperform	$413.23K	-2.13	―	―	-8.57%	-52.17%